Control of replication and gene expression by ADP-ribosylation of DNA in Mycobacterium tuberculosis
Mycobacterium tuberculosis maintains long-term infections characterised by the need to regulate growth and adapt to contrasting in vivo environments. Here we show that M. tuberculosis complex bacteria utilise reversible ADP-ribosylation of single-stranded DNA as a mechanism to coordinate stationary phase growth with transcriptional adaptation. The DNA modification is controlled by DarT, an ADP-ribosyltransferase, which adds ADP-ribose to thymidine, and DarG, which enzymatically removes this base modification. Using darG-knockdown M. bovis BCG, we map the first DNA ADP-ribosylome from any organism. We show that inhibition of replication by DarT is reversible and accompanied by extensive ADP-ribosylation at the origin of replication (OriC). In addition, we observe ADP-ribosylation across the genome and demonstrate that ADP-ribose-thymidine alters the transcriptional activity of M. tuberculosis RNA polymerase. Furthermore, we demonstrate that during stationary phase, DarT-dependent ADP-ribosylation of M. tuberculosis DNA is required to optimally induce expression of the Zur regulon, including the ESX-3 secretion system and multiple alternative ribosome proteins. Thus, ADP-ribosylation of DNA can provide a mechanistic link through every aspect of DNA biology from replication to transcription to translation.
Authors
- M. Schuller (ORCID: https://orcid.org/0000-0002-1551-0359)
- Ivan Ahel
- Suzie Hingley‐Wilson (ORCID: https://orcid.org/0000-0002-6514-1424)
- Rachel E. Butler (ORCID: https://orcid.org/0000-0002-6018-7765)
- Alex Couto Alves
- Graham R. Stewart (ORCID: https://orcid.org/0000-0002-6867-6248)
- Jayanta Mukhopadhyay
- Jim Barber
- Rohit Jaiswal
- Emily Wasson (ORCID: https://orcid.org/0000-0002-8382-0631)
Institutions
- Bose Institute (IN)
- University of Surrey (GB)
- University of Oxford (GB)
- University of Southampton (GB)
Publication Details
- Journal
- The EMBO Journal
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1038/s44318-025-00451-y
- Citations
- 4
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Wellcome Trust
- Cancer Research UK
- Biotechnology and Biological Sciences Research Council